SEC Comment Letter 0000000000-24-001432 to CalciMedica, Inc. (CALC)
CalciMedica, Inc.
Date: Feb. 6, 2024 · CIK: 0001534133 · Accession: 0000000000-24-001432
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276793
Letter
United States securities and exchange commission logo February 6, 2024 A. Rachel Leheny, Ph.D. Chief Executive Officer CalciMedica, Inc. 505 Coast Boulevard South, Suite 307 La Jolla, CA 92037 Re:CalciMedica, Inc. Registration Statement on Form S-3 Filed January 31, 2024 File No. 333-276793 Dear A. Rachel Leheny: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlos Ramirez, Esq.
Show Raw Text
United States securities and exchange commission logo
February 6, 2024
A. Rachel Leheny, Ph.D.
Chief Executive Officer
CalciMedica, Inc.
505 Coast Boulevard South, Suite 307
La Jolla, CA 92037
Re:CalciMedica, Inc.
Registration Statement on Form S-3
Filed January 31, 2024
File No. 333-276793
Dear A. Rachel Leheny:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Carlos Ramirez, Esq.